AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Resmed DRC

37.670

+0.3400.91%

Volume:765.83K

Turnover:28.79M

Market Cap:55.23B

PE:29.45

High:37.700

Open:37.330

Low:37.150

Close:37.330

Loading ...

Overview Company News Filings

19 ASX stocks that should be on your radar

VEEV Stock Falls Despite Latest Announcement to Enable AI Innovation

2 Reasons to Like RMD and 1 to Stay Skeptical

The ultimate ASX growth shares to buy with $2,000 in March

AMED Q4 Earnings and Revenues Miss, Margins Dip, Stock Rises

Leading brokers name 3 ASX shares to buy today

Why this ASX 200 stock could be one of the best to buy in the Asia-Pacific

TransMedics Stock Rises as Q4 Earnings & Revenues Beat Estimates

OPK Stock Gains Following Q4 Earnings Beat, Gross Margin Expands

Teleflex Stock Rises on Q4 Earnings Beat, Gross Margin Crashes

Chemed Q4 Earnings & Revenues Top, Stock Climbs, Margins Contract

ResMed Inc. Stock Falls Thursday, Still Outperforms Market

How to build a million-dollar ASX share portfolio starting with $5,000

TNDM Stock Falls in Aftermarket Following Q4 Earnings and Revenue Miss

EYE Q4 Loss Narrower Than Expected, Margins Rise, Stock Surges

MMSI Stock Gains in Pre-Market Post Q4 Earnings Beat, Margins Up

MASI Stock Gains Following Q4 Earnings Beat, Gross Margin Contracts

Here's Why ResMed (RMD) is a Strong Growth Stock

Alcon Q4 Earnings Beat, Margins Rise, Stock Remains Stable in Afterhours

ResMed’s Fifth Annual Global Sleep Survey Reveals a World Struggling with Poor Sleep

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RMD.AU/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RMD.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RMD.AU\",,,,,undefined,":{"symbol":"RMD.AU","market":"AU","secType":"STK","nameCN":"Resmed DRC","latestPrice":37.67,"timestamp":1746598320000,"preClose":37.33,"halted":0,"volume":765834,"delay":0,"nameEN":"Resmed DRC","floatShares":145691036,"shares":1466188140,"eps":1.2789131253691408,"marketStatus":"Not Yet Opened","change":0.34,"latestTime":"05-07 16:12:00 AEST","open":37.33,"high":37.7,"low":37.15,"amount":28788045,"amplitude":0.014733,"askPrice":37.68,"askSize":20000,"bidPrice":37.3,"bidSize":90,"shortable":3,"etf":0,"ttmEps":1.2789131253691408,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1746662400000},"marketStatusCode":0,"adr":0,"adrRate":1,"exchange":"ASX","adjPreClose":37.33,"dividendRate":0.008106,"openAndCloseTimeList":[[1746576000000,1746597600000]],"volumeRatio":0.9281889046614755,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RMD.AU\",,,,,undefined,":{"symbol":"RMD.AU","floatShares":145691036,"roa":"14.01%","roe":"25.81%","lyrEps":0.968874,"volumeRatio":0.9281889046614755,"shares":1466188140,"dividePrice":0.305389,"high":37.7,"amplitude":0.014733,"preClose":37.33,"low":37.15,"week52Low":26.887,"pbRate":"6.42","psRate":"7.10","week52High":40.571,"institutionHeld":0,"latestPrice":37.67,"committee":-0.99104,"eps":1.2789131253691408,"divideRate":0.008106,"volume":765834,"delay":0,"ttmEps":1.2789131253691408,"open":37.33,"prevYearClose":36.609,"prevWeekClose":37.178,"prevMonthClose":36.599,"prevQuarterClose":34.883,"fiveDayClose":36.599,"twentyDayClose":33.786,"sixtyDayClose":37.525},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RMD.AU\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517951957","title":"19 ASX stocks that should be on your radar","url":"https://stock-news.laohu8.com/highlight/detail?id=2517951957","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517951957?lang=en_us&edition=fundamental","pubTime":"2025-03-05 13:29","pubTimestamp":1741152599,"startTime":"0","endTime":"0","summary":"Please note this interview was filmed on 3 March 2025. Another reporting season is in the books, so it’s time again to sit down with the Yarra Capital Management Equities team to discuss the key takeaways and, more importantly, what lies ahead.I was joined by Marcus Ryan, Michael Steele, and Joel Fleming, who represent the entire market cap spectrum, from micro to large caps. Below is a summary of the key themes and stocks discussed but, if you want the full experience, make sure to watch the video.According to Ryan, one of the key highlights of the season was that many companies demonstrated strong cost control, leading to better-than-expected margins despite only 10% of ASX 200 companies beating sales expectations.This trend was evident across various sectors, including resources and building materials. Boral, now within Seven Group , exemplified this improvement.After strong performance over the past 12 months, banks declined around. earnings , with growing competition and margin pr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/19-asx-stocks-that-should-be-on-your-radar","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/19-asx-stocks-that-should-be-on-your-radar","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK7506","APE.AU","RIO.AU","NST.AU","SFR.AU","BK7501","BK7007","MGH.AU","TCL.AU","XKO.AU","BK7129","FPH.AU","APA.AU","VSL.AU","RWC.AU","BK7090","BK7148","BK7104","XJO.AU","RMD.AU","BK7031","EVN.AU","BK7126","SGH.AU","BSL.AU","XAO.AU","BK7143","BK7055","BK7511","BHP.AU","BK7507","BK7120","BK7110","SGM.AU","BK7095","ANN.AU","BK7016","BK7012","EOL.AU"],"gpt_icon":0},{"id":"2517077286","title":"VEEV Stock Falls Despite Latest Announcement to Enable AI Innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2517077286","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517077286?lang=en_us&edition=fundamental","pubTime":"2025-03-05 01:11","pubTimestamp":1741108260,"startTime":"0","endTime":"0","summary":"Veeva Systems Inc. VEEV, on Thursday, announced that Direct Data API is now included for no additional license fee as part of Veeva Vault Platform. This is expected to enable AI innovation in the life sciences industry.It is worth noting that Veeva Direct Data API is a new class of API that makes Veeva Vault data accessible at a significantly faster pace, unlike traditional APIs, and is transactionally sound across large datasets.The latest inclusion of the Direct Data API is expected to make the Veeva Vault Platform more attractive to the life sciences industry, thus boosting its overall business.Following the announcement, shares of the company lost nearly 3.6% till yesterday’s closing.In January, Veeva Systems announced a product partnership with Zifo to aid biopharmas modernize quality control  operations. By combining Veeva LIMS with Zifo's data integration and management platform, qcKen, companies will be able to import data directly from any source document or other LIMS into Ve","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/veev-stock-falls-despite-latest-171100091.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BJJMRZ35.SGD","LU0072461881.USD","LU1291159041.SGD","IE00B4R5TH58.HKD","LU0114720955.EUR","VEEV","BK4082","LU0345769631.USD","LU0211327993.USD","BK4504","RMD.AU","IE00B2B36J28.USD","LU2242649171.HKD","LU0267386448.USD","LU1023059063.AUD","LU1267930813.SGD","LU2265009873.SGD","LU0823417653.USD","LU1989764664.SGD","IE00BFTCPJ56.SGD","LU0950375773.USD","LU0353189763.USD","LU0310799852.SGD","BK4167","LU0154236417.USD","LU2362540622.SGD","LU0310800965.SGD","LU0353189680.USD","LU1571399168.USD","LU2087625088.SGD","LU2177674079.SGD","LU0792757196.USD","LU1804176565.USD","IE0009355771.USD","BK4175","LU2362541513.USD","LU2506952170.USD","LU0823416689.USD","CAH","LU1057294990.SGD","LU1989772923.USD","BK4528","LU2112291526.USD","RMD","BSX","LU2506952097.USD","LU0052756011.USD","LU1718418525.SGD","LU0528227936.USD","BK4581","LU2491050071.SGD"],"gpt_icon":0},{"id":"2516221096","title":"2 Reasons to Like RMD and 1 to Stay Skeptical","url":"https://stock-news.laohu8.com/highlight/detail?id=2516221096","media":"StockStory","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516221096?lang=en_us&edition=fundamental","pubTime":"2025-03-04 17:03","pubTimestamp":1741079020,"startTime":"0","endTime":"0","summary":"Since September 2024, ResMed has been in a holding pattern, posting a small loss of 4.8% while floating around $233.10. The stock also fell short of the S&P 500’s 6.2% gain during that period.Or does the price properly account for its business quality and fundamentals?Find out in our full research report, it’s free.Founded in 1989 in Australia, ResMed  is a medical device company specializing in products for chronic health conditions like sleep apnea, asthma, neuromuscular disorders, and others.We can better understand Patient Monitoring companies by analyzing their constant currency revenue. This metric excludes currency movements, which are outside of ResMed’s control and are not indicative of underlying demand.Over the last two years, ResMed’s constant currency revenue averaged 14.8% year-on-year growth. This performance was impressive and shows it can expand quickly on a global scale regardless of the macroeconomic environment.Stocks that made our list in 2019 include now familiar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/2-reasons-rmd-1-stay-090340229.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4548","LU2177674079.SGD","BK4588","BK4504","BK4082","BK4567","RMD","LU2008162690.USD","RMD.AU","BK4585"],"gpt_icon":1},{"id":"2516364722","title":"The ultimate ASX growth shares to buy with $2,000 in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2516364722","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516364722?lang=en_us&edition=fundamental","pubTime":"2025-03-04 13:05","pubTimestamp":1741064700,"startTime":"0","endTime":"0","summary":"There are a lot of ASX growth shares for investors to choose from on the Australian share market. To narrow things down, let's take a look at some that could be considered among the best of the best. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/04/the-ultimate-asx-growth-shares-to-buy-with-2000-in-march/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["IE00B19Z3B42.SGD","BK7503","IE0004091025.USD","LU0096364046.USD","LU1868836757.USD","IE00BSNM7G36.USD","LU1668664300.SGD","BK4504","BK4588","BK7007","LU2237443549.SGD","BK4516","BK4552","LU1868837300.USD","LU2471134879.HKD","LU2750360997.AUD","LU2237443895.HKD","BK7094","LU2471134796.USD","BK4550","LU2750360641.GBP","LU2237443465.HKD","LU1868836591.USD","PME.AU","RMD.AU","BK7501","LU2237443622.USD","LU0106831901.USD","LU2471134952.CNY","IE0004086264.USD","BK4585","LU2237443382.USD","LU0061475181.USD","LU1791807156.HKD","IE00BFXG1179.USD","LU2237438978.USD","LU2471134523.USD","IE0002270589.USD","LU2237443978.SGD","BK4127","IE0034235188.USD","LU1868836914.USD","LU1868837136.USD","BK4533","BK7016","IE00B19Z3581.USD","WTC.AU"],"gpt_icon":1},{"id":"2516635923","title":"AMED Q4 Earnings and Revenues Miss, Margins Dip, Stock Rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2516635923","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516635923?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:14","pubTimestamp":1741000440,"startTime":"0","endTime":"0","summary":"Amedisys, Inc. AMED reported fourth-quarter 2024 adjusted earnings per share  of 96 cents, which rose 2.1% year over year. However, the metric missed the Zacks Consensus Estimate by 8.6%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The quarter’s adjustments include certain merger-related expenses and other /expenses, net.GAAP loss was 62 cents per share against EPS of 59 cents in the corresponding period of 2023.Full-year 2024 adjusted EPS was $4.32, up 0.5% year over year.Following the earnings announcement, AMED’s shares gained 0.1% last Thursday.Net service revenues totaled $598.0 million, up 4.8% year over year. The top line missed the Zacks Consensus Estimate marginally by 0.02%.Full-year 2024 net service revenues were $2.35 billion, up 4.9% year over year.Net service revenues from the Home Health division totaled $377.0 million, up 5% year over year.Within the segment, Medicare revenues of $212.4 million decreased 3.9% year over year. Non-Medicare revenu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amed-q4-earnings-revenues-miss-111400849.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RMD","RMD.AU","CAH","AMED"],"gpt_icon":1},{"id":"2516788345","title":"Leading brokers name 3 ASX shares to buy today","url":"https://stock-news.laohu8.com/highlight/detail?id=2516788345","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516788345?lang=en_us&edition=fundamental","pubTime":"2025-03-03 08:54","pubTimestamp":1740963259,"startTime":"0","endTime":"0","summary":"With so many shares to choose from on the Australian share market, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work fo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/03/leading-brokers-name-3-asx-shares-to-buy-today-3-march-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU1868836914.USD","LU2237443382.USD","BK4504","BK4516","BK4552","IE0002270589.USD","LU1668664300.SGD","LIF","LNW.AU","BK7016","LU1868836757.USD","BK7007","BK4127","BK4585","IE0034235188.USD","LU2750360641.GBP","LU1868837136.USD","BK4550","LU1868836591.USD","LU2471134952.CNY","IE0004086264.USD","IE00BFXG1179.USD","RMD.AU","LU2237438978.USD","LU2471134879.HKD","IE00B19Z3581.USD","LU2471134523.USD","BK7501","LU2237443465.HKD","LU2237443895.HKD","LU2750360997.AUD","LU2237443622.USD","LU2471134796.USD","LU1868837300.USD","BK4588","BK7078","LU0096364046.USD","LU1791807156.HKD","LU2237443549.SGD","IE00BSNM7G36.USD","360.AU","BK4533","IE00B19Z3B42.SGD","LU2237443978.SGD","BK4023","LU0061475181.USD","IE0004091025.USD","LU0106831901.USD"],"gpt_icon":1},{"id":"2516254746","title":"Why this ASX 200 stock could be one of the best to buy in the Asia-Pacific","url":"https://stock-news.laohu8.com/highlight/detail?id=2516254746","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516254746?lang=en_us&edition=fundamental","pubTime":"2025-03-03 05:54","pubTimestamp":1740952481,"startTime":"0","endTime":"0","summary":"ResMed Inc.  shares have been on form over the past 12 months. During this time, the sleep disorder treatment company's shares have rallied almost 40% higher. The good news for investors is that it may not be too late to buy this high-quality ASX 200 stock according to analysts at Goldman Sachs. In fact, not only does the broker think that outsized returns are on the cards over the next 12 months, but it feels that ResMed could be one of the best shares to buy in the whole Asia-Pacific region. Why is ResMed one of the best ASX 200 stocks to buy?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/03/why-this-asx-200-stock-could-be-one-of-the-best-to-buy-in-the-asia-pacific-2/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU2237443978.SGD","IE0004091025.USD","BK4533","LU2471134796.USD","LU2471134879.HKD","LU2237443622.USD","LU2750360641.GBP","IE0034235188.USD","LU0106831901.USD","LU2237443549.SGD","LU1868836757.USD","BK7501","LU2237443382.USD","LU2471134523.USD","IE00BFXG1179.USD","LU1791807156.HKD","BK4516","LU0061475181.USD","LU0096364046.USD","LU2237443465.HKD","LU2237443895.HKD","RMD.AU","BK4127","IE0002270589.USD","IE0004086264.USD","LU1868837300.USD","BK4552","LU1868837136.USD","BK4588","LU1868836914.USD","IE00BSNM7G36.USD","BK4504","LU2471134952.CNY","IE00B19Z3581.USD","LU2237438978.USD","BK7007","LU1668664300.SGD","LU1868836591.USD","BK4585","IE00B19Z3B42.SGD","LU2750360997.AUD","BK4550"],"gpt_icon":0},{"id":"2516088383","title":"TransMedics Stock Rises as Q4 Earnings & Revenues Beat Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2516088383","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516088383?lang=en_us&edition=fundamental","pubTime":"2025-03-01 00:30","pubTimestamp":1740760200,"startTime":"0","endTime":"0","summary":"TransMedics Group, Inc.TMDX reported fourth-quarter 2024 earnings per share  of 19 cents, which beat the Zacks Consensus Estimate of 18 cents by 5.6%. The company recorded an EPS of 12 cents in the year-ago period.TransMedics registered revenues of $121.6 million, up 49.8% year over year. The figure surpassed the Zacks Consensus Estimate by 10.2%. The year-over-year increase in sales was driven by the rise in utilization of the Organ Care System  across all three organs and additional revenues generated by TransMedics logistics services.Shares of TMDX were up 6.9% during after-hours trading on Feb. 27, likely following the company’s strong quarterly performance. However, the company’s shares have plunged 56.8% in the past six months compared with theindustry’s decline of 2.4%. The S&P 500 Index was up 7% during the same timeframe.TransMedics has three FDA-approved OCS products, each for heart, lung and liver transplantations. TMDX’s OCS products are the only FDA-approved portable, mult","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/transmedics-stock-rises-q4-earnings-163000908.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TMDX","RMD","RMD.AU","BSX","CAH"],"gpt_icon":0},{"id":"2516372627","title":"OPK Stock Gains Following Q4 Earnings Beat, Gross Margin Expands","url":"https://stock-news.laohu8.com/highlight/detail?id=2516372627","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516372627?lang=en_us&edition=fundamental","pubTime":"2025-03-01 00:21","pubTimestamp":1740759660,"startTime":"0","endTime":"0","summary":"OPKO Health, Inc. OPK delivered earnings per share  of a penny in the fourth quarter of 2024 against the year-ago period’s loss of 9 cents per share and the Zacks Consensus Estimate of a loss of 11 cents per share.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Full-year 2024 loss per share was 8 cents, narrower than the comparable 2023 period and the Zacks Consensus Estimate of loss per share of 25 cents.OPKO Health registered revenues of $183.6 million in the fourth quarter, up 0.9% year over year. The figure topped the Zacks Consensus Estimate by 18.4%.OPKO Health manages its operations through two reportable segments – Diagnostics and Pharmaceuticals.OPKO Health, Inc. price-consensus-eps-surprise-chart | OPKO Health, Inc. Quote. In the quarter under review, OPKO Health’s gross profit jumped 89.3% year over year to $84.6 million. The gross margin expanded a huge 2150 basis points to 46.1%. We had projected a gross margin of 34.1% in the fourth quarter of 2024.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/opk-stock-gains-following-q4-162100991.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RMD.AU","BSX","OPK","RMD","CAH"],"gpt_icon":1},{"id":"2516797783","title":"Teleflex Stock Rises on Q4 Earnings Beat, Gross Margin Crashes","url":"https://stock-news.laohu8.com/highlight/detail?id=2516797783","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516797783?lang=en_us&edition=fundamental","pubTime":"2025-02-28 22:40","pubTimestamp":1740753600,"startTime":"0","endTime":"0","summary":"Teleflex Incorporated TFX posted fourth-quarter 2024 adjusted earnings per share  from continuing operations of $3.89, up 15.1% from the year-ago quarter’s figure. The metric topped the Zacks Consensus Estimate by 0.8%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.GAAP loss per share was $2.95 compared to EPS of $0.66 in the prior-year period.The full-year adjusted EPS from continuing operations was $14.01, up 3.6% year over year. The figure topped the Zacks Consensus Estimate by 0.2%.Following the announcement, shares of the company rose 0.6% in yesterday’s after-market trading.Net revenues rose 2.8% year over year  to $795.4 million. However, the metric missed the Zacks Consensus Estimate by 2.2%.Full-year 2024 net revenues were $3.05 billion, up 2.4% year over year. The figure missed the Zacks Consensus Estimate by 1%.Teleflex has three reportable segments: Americas, EMEA  and Asia .Revenues from Asia  rose 5.9% to $93.6 million . Our model’s projection was ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/teleflex-stock-rises-q4-earnings-144000583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RMD.AU","CAH","RMD","TFX"],"gpt_icon":0},{"id":"2514375925","title":"Chemed Q4 Earnings & Revenues Top, Stock Climbs, Margins Contract","url":"https://stock-news.laohu8.com/highlight/detail?id=2514375925","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514375925?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:30","pubTimestamp":1740749400,"startTime":"0","endTime":"0","summary":"Chemed Corporation CHE reported fourth-quarter 2024adjusted earnings per share  of $6.83, which rose 3.5% year over year. The figure surpassed the Zacks Consensus Estimate by 0.5%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The company’s GAAP EPS was $6.02, up 2% from last year’s reported figure.For the full year, the adjusted EPS was $23.13, reflecting a 13.9% increase from the year-ago period.Revenues in the reported quarter improved 9.2% year over year to $640 million. The metric topped the Zacks Consensus Estimate by 1.7%.Full-year revenues were $2.43 billion, up 7.4% from last year’s revenues.Since the earnings announcement on Feb. 26, CHE stock surged 7.3%, finishing at $586.12 yesterday.In the fourth quarter, net patient revenues totaled $411 million, up 17.4% year over year.The segment reported sales of $229 million, down 2.9% year over year.Total Roto-Rooter branch commercial revenues edged up 0.4% year over year. This consisted of a 0.2% rise in dra","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chemed-q4-earnings-revenues-top-133000993.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["RMD","CHE","RMD.AU"],"gpt_icon":0},{"id":"2514355288","title":"ResMed Inc. Stock Falls Thursday, Still Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2514355288","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514355288?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:57","pubTimestamp":1740693420,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of ResMed Inc.  shed 1.42% to $231.28 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index  falling 1.59% to 5,861.57 and Dow Jones Industrial Average  falling 0.45% to 43,239.50.This was the stock's second consecutive day of losses.ResMed Inc. closed 12.08% below its 52-week high of $263.05, which the company reached on January 30th.Trading volume  remained 503,926 below its 50-day average volume of 934,600.Data source: Dow Jones Market Data, FactSet. Data compiled February 27, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD","RMD.AU"],"gpt_icon":0},{"id":"2514334473","title":"How to build a million-dollar ASX share portfolio starting with $5,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2514334473","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514334473?lang=en_us&edition=fundamental","pubTime":"2025-02-28 01:41","pubTimestamp":1740678060,"startTime":"0","endTime":"0","summary":"Many investors dream of building a million-dollar portfolio, but few realise that it doesn't take a massive upfront investment to achieve this goal. With a combination of patience, consistency, and a ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/28/how-to-build-a-million-dollar-asx-share-portfolio-starting-with-5000/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7021","BK7007","BK7501","RMD.AU","AX1.AU","BK7016","BRN.AU"],"gpt_icon":0},{"id":"2514386064","title":"TNDM Stock Falls in Aftermarket Following Q4 Earnings and Revenue Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2514386064","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514386064?lang=en_us&edition=fundamental","pubTime":"2025-02-27 21:44","pubTimestamp":1740663840,"startTime":"0","endTime":"0","summary":"Tandem Diabetes Care, Inc. TNDM posted a fourth-quarter 2024 loss of 44 cents per share compared with the year-ago quarter’s reported loss of 27 cents. The figure missed the Zacks Consensus Estimate of a loss of 25 cents per share.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.On a GAAP basis, the company reported earnings of 1 cent per share compared to the year-ago loss of 46 cents.Full-year 2024 loss was $1.91 per share compared with the year-ago reported loss of $1.57. The figure missed the Zacks Consensus Estimate of a loss of $1.73.Following the earnings announcement, TNDM stock fell 18.6% in aftermarket trading yesterday.From September 2022 through February 2024, TNDM offered the Tandem Choice Program to eligible t:slim X2 customers to provide a pathway to the ownership of its newest hardware platform, Tandem Mobi, when available. Based on that, Tandem Diabetes is now reporting adjusted revenues as well.For the full year, GAAP sales are estimated to be in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tndm-stock-falls-aftermarket-following-134400690.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RMD.AU","CAH","TNDM","RMD"],"gpt_icon":0},{"id":"2514386065","title":"EYE Q4 Loss Narrower Than Expected, Margins Rise, Stock Surges","url":"https://stock-news.laohu8.com/highlight/detail?id=2514386065","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514386065?lang=en_us&edition=fundamental","pubTime":"2025-02-27 21:31","pubTimestamp":1740663060,"startTime":"0","endTime":"0","summary":"National Vision Holdings, Inc. EYE delivered a loss of 4 cents in the fourth quarter of 2024compared with the year-ago period’s loss of 2 cents. However, the figure was narrower than the Zacks Consensus Estimate of a loss of 5 cents.Find the latest EPS estimates and surprises on ZacksEarnings Calendar.The GAAP loss from continuing operations was 37 cents per share compared with a loss of 19 cents in the prior-year quarter.The full-year 2024 GAAP loss from continuing operations was 35 cents per share against earnings of 5 cents in 2023.In fiscal 2024, the company ceased its Walmart and AC Lens operations. Accordingly, the consolidated financial statements classify the results of the former Legacy segment and the substantial majority of AC Lens operations as discontinued operations for all periods presented.As of Dec. 28, 2024, National Vision operates under one reportable segment, Owned & Host.National Vision Holdings, Inc. Price, Consensus and EPS Surprise. National Vision Holdings, In","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/eye-q4-loss-narrower-expected-133100012.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0792757196.USD","LU0728928796.USD","LU1571399168.USD","LU1267930490.SGD","LU0006061336.USD","LU0211327993.USD","LU0162691827.USD","LU0566484027.USD","CAH","LU2008162690.USD","BK4588","EYE","LU0053671581.USD","LU1084165304.USD","LU1880398471.USD","BK4504","LU0211328371.USD","RMD.AU","SG9999001440.SGD","PODD","LU1559883803.SGD","LU0310800965.SGD","BK4585","LU0310799852.SGD","LU2177674079.SGD","LU1119994496.HKD","RMD","BK4551","LU0889566641.SGD","LU1267930227.SGD","BK4200","BK4566","BK4567","LU0154236417.USD","LU0128525689.USD","BK4175","BK4082","LU1267930813.SGD","LU1880398554.USD","LU0052756011.USD","BK4548","LU0072461881.USD","LU1261432733.SGD"],"gpt_icon":0},{"id":"2514652938","title":"MMSI Stock Gains in Pre-Market Post Q4 Earnings Beat, Margins Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2514652938","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514652938?lang=en_us&edition=fundamental","pubTime":"2025-02-27 00:06","pubTimestamp":1740585960,"startTime":"0","endTime":"0","summary":"Merit Medical Systems, Inc. MMSI reported fourth-quarter 2024 adjusted earnings per share  of 93 cents, up 25.7% from the year-ago quarter. The bottom line surpassed the Zacks Consensus Estimate by 12.1%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.GAAP EPS for the quarter was 46 cents, down by a penny year over year.Full-year 2024 adjusted EPS was $3.46, up 21.4% from the comparable year-ago period. The metric topped the Zacks Consensus Estimate by 2.7%.Revenues grossed $355.2 million in the reported quarter, up 9.4% year over year on a reported basis. The metric topped the Zacks Consensus Estimate by 0.9%.Total revenues at constant exchange rate  increased 10.1% year over year, whereas CER, organic revenues increased 6.1%.International sales amounted to $141.6 million, up 4.2% year over year on a reported basis and 5.3% at CER. This figure compares to our fourth-quarter projection of $138.9 million.PI product line revenues were $140.4 million, up 4.6% on a r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mmsi-stock-gains-pre-market-160600563.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RMD.AU","BSX","CAH","MMSI","RMD","POST"],"gpt_icon":0},{"id":"2514865266","title":"MASI Stock Gains Following Q4 Earnings Beat, Gross Margin Contracts","url":"https://stock-news.laohu8.com/highlight/detail?id=2514865266","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514865266?lang=en_us&edition=fundamental","pubTime":"2025-02-27 00:04","pubTimestamp":1740585840,"startTime":"0","endTime":"0","summary":"Masimo Corporation MASI delivered adjusted earnings per share  of $1.80 in the fourth quarter of 2024, up 44% year over year. The figure beat the Zacks Consensus Estimate by 20.8%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The adjustments include acquired intangible asset amortization, and acquisitions, integrations, divestitures, and related costs, among others.GAAP loss per share for the quarter was $6.52  against the year-ago period’s EPS of 63 cents.Full-year 2024 adjusted EPS was $4.40, up 16.1% from the comparable 2023 period. The metric topped the Zacks Consensus Estimate by 7.3%.Masimo registered revenues of $600.7 million in the fourth quarter, up 9.4% year over year on a reported basis. The figure beat the Zacks Consensus Estimate by 0.8%.Per management, shipments of non-invasive technology boards and instruments, excluding handheld and fingertip pulse oximeters, totaled 65,000 in the fourth quarter of 2024.Healthcare revenues in the fourth quarter","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/masi-stock-gains-following-q4-160400408.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CAH","MASI","RMD.AU","RMD","BSX"],"gpt_icon":0},{"id":"2514868169","title":"Here's Why ResMed (RMD) is a Strong Growth Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2514868169","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514868169?lang=en_us&edition=fundamental","pubTime":"2025-02-26 22:45","pubTimestamp":1740581109,"startTime":"0","endTime":"0","summary":"It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors.Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term.Why This 1 Growth Stock Should Be On Your Watchlist. Growth investors build their portfolios around companies that are financially strong and have a bright future, and the Growth Style Score helps take projected and historical earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.ResMed, Inc. holds a major position as designer, manufacturer, as well as a distributor in the worldwide market for generators, masks, and related accessories for the treatment of sleep-diso","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-resmed-rmd-strong-144509614.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["LU2177674079.SGD","BK4504","BK7007","BK4548","BK4567","RMD","LU2008162690.USD","RMD.AU","BK7501","BK4585","BK4082","BK4588"],"gpt_icon":1},{"id":"2514858065","title":"Alcon Q4 Earnings Beat, Margins Rise, Stock Remains Stable in Afterhours","url":"https://stock-news.laohu8.com/highlight/detail?id=2514858065","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514858065?lang=en_us&edition=fundamental","pubTime":"2025-02-26 20:34","pubTimestamp":1740573240,"startTime":"0","endTime":"0","summary":"Alcon, Inc. ALC delivered fourth-quarter 2024 core earnings per share  of 72 cents, up 2.9% from the year-ago quarter’s figure . The figure topped the Zacks Consensus Estimate by 2.9%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Alcon reports “core” results based on non-IFRS  measures. In the fourth quarter, the company’s EPS was 57 cents, down 33.7%  year over year.The full-year core EPS was $3.05, up 11.3% year over year . The figure topped the Zacks Consensus Estimate by 0.7%.Despite the positive figures, ALC's stock price remained relatively stable in after-hours trading following the earnings release.Net sales to third parties in the quarter under review were $2.48 billion, which surpassed the Zacks Consensus Estimate by 0.7%. The top line also increased 6.2% from the year-ago quarter’s level .Full-year 2024 net sales to third parties totaled $9.84 billion, up 5% year over year. The figure surpassed the Zacks Consensus Estimate by 0.2%.Alcon reports ope","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alcon-q4-earnings-beat-margins-123400562.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RMD","RMD.AU","ALC","CAH"],"gpt_icon":0},{"id":"2514074530","title":"ResMed’s Fifth Annual Global Sleep Survey Reveals a World Struggling with Poor Sleep","url":"https://stock-news.laohu8.com/highlight/detail?id=2514074530","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514074530?lang=en_us&edition=fundamental","pubTime":"2025-02-26 16:00","pubTimestamp":1740556800,"startTime":"0","endTime":"0","summary":"New insights from 30,026 people across 13 markets show the global scale of poor sleep and its impact on health, work, and relationships. 7 out of 10 employed respondents have called in sick at least once in their career due to poor sleep.18% of couples reported sleeping in separate rooms due to snoring and restlessness.SAN DIEGO, Feb. 26, 2025  -- ResMed , a global health technology leader focused on sleep, breathing, and care delivered in the home, today unveiled the findings of its fifth annual Global Sleep Survey. With insights from 30,026 respondents across 13 markets, the study underscores a widespread global sleep crisis, with people losing an average of nearly three nights of restorative sleep each week.Despite a trend towards growing awareness of sleep’s importance, many continue to suffer in silence and remain trapped in a cycle of exhaustion. The research reveals that nearly one in four (22%) respondents choose to just live with poor sleep rather than seek help. With poor sle","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/resmed-fifth-annual-global-sleep-080000515.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4504","BK4548","RMD","RMD.AU","BK4567","LU2177674079.SGD","BK4588","LU2008162690.USD","BK4585","BK4082"],"gpt_icon":1}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RMD.AU\",params:#limit:5,,,undefined,":[{"date":"2025-05-07","symbol":"RMD.AU","amount":0.053,"announcedDate":"2025-04-24","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-05-08","defaultRemindTime":1746576000000,"name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-12","payableDate":"2025-05-08","currency":"USD","dateTimestamp":1746540000000,"payDate":"2025-06-12"},{"date":"2025-02-12","symbol":"RMD.AU","amount":0.053,"announcedDate":"2025-01-31","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-02-13","name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-20","payableDate":"2025-02-13","currency":"USD","dateTimestamp":1739278800000,"payDate":"2025-03-20"},{"date":"2024-11-06","symbol":"RMD.AU","amount":0.053,"announcedDate":"2024-10-25","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2024-11-07","name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-12","payableDate":"2024-11-07","currency":"USD","dateTimestamp":1730811600000,"payDate":"2024-12-12"},{"date":"2024-08-14","symbol":"RMD.AU","amount":0.053,"announcedDate":"2024-08-02","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2024-08-15","defaultRemindTime":1723593600000,"name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-19","payableDate":"2024-08-15","currency":"USD","dateTimestamp":1723557600000,"payDate":"2024-09-19"},{"date":"2024-05-08","symbol":"RMD.AU","amount":0.048,"announcedDate":"2024-04-26","type":"dividend","market":"AU","newRecordDate":"2024-05-09","defaultRemindTime":1715126400000,"name":"Resmed DRC","recordDate":"2024-06-13","payableDate":"2024-05-09","currency":"USD","dateTimestamp":1715090400000,"payDate":"2024-06-13"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RMD.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-08-19","recordDate":"2020-08-20","paymentDate":"2020-09-24","value":0.039,"currency":"USD"},{"executeDate":"2020-11-11","recordDate":"2020-11-12","paymentDate":"2020-12-17","value":0.039,"currency":"USD"},{"executeDate":"2021-02-10","recordDate":"2021-02-11","paymentDate":"2021-03-18","value":0.039,"currency":"USD"},{"executeDate":"2021-05-12","recordDate":"2021-05-13","paymentDate":"2021-06-17","value":0.039,"currency":"USD"},{"executeDate":"2021-08-18","recordDate":"2021-08-19","paymentDate":"2021-09-23","value":0.042,"currency":"USD"}]}}